MIMEDX is the latest addition to the RegeneratOR Innovation Accelerator, located in the Regenerative Medicine Hub (RegenMed Hub), a rapidly growing regenerative medicine ecosystem based in the Innovation Quarter of Winston-Salem.
MIMEDX is a placental biologics company and a pioneer in placental tissue engineering. The company has distributed more than two million tissue allografts to date, primarily to address the needs of patients with acute and chronic non-healing wounds, and is also advancing a promising late-stage biologics pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. MIMEDX will be using the RegenMed Hub and its resources to further advance science related to the application of placental technologies in multiple areas of wound care and regenerative medicine, with the goal of developing new products and optimizing manufacturing processes in a way that progresses the delivery of safe, innovative, and evidence-based technologies for patients in a cost-effective manner.
Robert B. Stein, M.D., Ph.D., MIMEDX President, Regenerative Medicine and Biologics Innovation, said, “As a growth company within the Innovation Accelerator, MIMEDX’s Research, Development and Manufacturing teams can collaboratively advance the process efficiencies, biomanufacturing techniques and cutting-edge technologies required to drive innovation in regenerative medicine, specifically in the field of placental biologics. This opportunity furthers our ability to create and engineer products that address the unmet clinical needs of patients and providers, and advance the next generation of therapies for a broad range of disease states.”
The RegenMed Hub is the destination for regenerative medicine and is powered by the Wake Forest Institute for Regenerative Medicine (WFIRM), Innovation Quarter and the RegenMed Development Organization (ReMDO). The RegendMed Hub offers companies, like MIMEDX, access to unparalleled resources to advance regenerative medicine products and manufacturing.
To officially join the RegenMed Hub, MIMEDX secured space within the Innovation Accelerator, a program that supports innovation from research to commercialization for startups, growth companies, and established companies developing emerging technologies in regenerative medicine. Physical presence in the ecosystem gives unprecedented access to strategic partners, in addition to state-of-the-art biomanufacturing equipment, cutting edge technologies, industry expertise, talent, training program, and many more resources.
“We are looking forward to supporting MIMEDX through access to our Test Bed, which really offers up manufacturing-in-a-box solutions to optimize any manufacturing process with state-of-the-art equipment, technologies, and resources,” said Anthony Atala, MD, director of WFIRM.
Joshua Hunsberger, PhD, Chief Technology Officer of ReMDO, credits MIMEDX with trusting the vision. “We believe this region has a lot to offer in terms of helping these companies be successful, and, at the same time, we can advance the regenerative medicine field nationally.”
Gary Green, EdD, Chief Operating Officer of ReMDO, added, “Addressing manufacturing process optimization for companies in this space is the most critical need to enable these technologies to become widespread, affordable, and the next standard of care.”